Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4877 - Impact of Invasive Lobular Carcinoma in Latin American Breast Cancer Patients’ Disease-Free Survival. The new paradox.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Diana Flores-Díaz

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

D. Flores-Díaz1, C. Arce Salinas1, L. Flores2, F. Lara1, J.A. Matus Santos3, J.E. Bargallo Rocha3, V. Perez3, N. Reynoso-Noveron4, P.A. Cabrera3, A. Mohar4

Author affiliations

  • 1 Breast Medical Oncology, Instituto Nacional de Cancerología, 14080 - Mexico City/MX
  • 2 Epidemiology Department, Instituto Nacional de Salud Publica, Mexico City/MX
  • 3 Breast Cancer Department, Instituto Nacional de Cancerologia, 14080 - Mexico City/MX
  • 4 Epidemiology Breast Cancer Unit, Instituto Nacional de Cancerologia, 14080 - Mexico City/MX
More

Resources

Abstract 4877

Background

Traditionally invasive lobular breast carcinoma (LBC) has been considered a good prognosis histology. However, it has a unique molecular pathogenesis and different genomic profile. Our objective was to establish whether there is a difference in disease-free survival (DFS) between LBC and ductal carcinoma.

Methods

We evaluated a cohort of 5185 breast cancer patients with lobular and ductal carcinoma (DC) treated the at National Cancer Institute Mexico between 2006 and 2016. We compared presentation variables using the chi squared test. A Cox proportional hazards regression model was constructed to evaluate disease-free survival.

Results

With a median of 60 months follow-up, patients with LBC were older (p < 0.001), more frequently patients with Ki67 <18% (40.2% vs 28.6% p < 0.001), had lower nuclear grade (p < 0.001), and predominantly hormone receptor positive disease (77.9% vs 56.9% p < 0.001). Nevertheless, LBC patients had a higher recurrence rate (25.2% vs 21.1% p = 0.011). For both LBC and DC patients, factors that negatively influence 5-years DFS in the univariate analysis were stage III (71.9% vs 78.9% p < 0.001), Ki67>18% (83.3% vs 93.1% p = 0.016), low nuclear grade (82.1% vs 95.9% p < 0.001), triple negative (46.7% vs 71.8% p = 0.002), and Her2 positive (72.4% vs 84.5% p = 0.023). In the multivariate analysis patients with stage III, (OR 10.8, 95%CI 5.9–19.9), high nuclear grade (OR 1.5, 95%CI 1.0-2.4), Ki67 >18 (OR 1.5, 95%CI 1.1–1.9), triple negative phenotype (OR 2.7, 95% CI 1.1-6.6) and lobular carcinoma (OR 1.8, 95%CI 1.1-2.7) are independent negative factors for DFS.

Conclusions

The presence of lobular invasive carcinoma is an independent negative factor for DFS. Despite the high rate of good prognosis elements in pathological reports, lobular carcinoma seems to be another disease and we need to evaluate deeply new and old treatment strategies to provide better disease control. Particulary in clinical stage III, Latin America has a challenge to be aware of it.

Clinical trial identification

Legal entity responsible for the study

Instituto Nacional de Cancerología, Mexico.

Funding

Has not received any funding.

Editorial Acknowledgement

Our patients

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings